ECM
RVNC

Elgethun Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Elgethun Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-600
Closed -$12K – 235
2016
Q4 		$12K Buy
+600
New +$10K 0.01% 205

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Elgethun Capital Management's RVNC Position: Q1 2017 in Review

Elgethun Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2017, closing a stake of 600 shares — an estimated $12K sold.

Elgethun Capital Management first reported a position in RVNC in Q4 2016 and held it in 1 quarter. The position peaked at $12K in Q4 2016. 78 funds tracked by Wall St. Rank hold RVNC as of Q1 2017.

  • Elgethun Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Elgethun Capital Management sold 600 Revance Therapeutics, Inc. shares in Q1 2017, an estimated $12K.
  • Elgethun Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Elgethun Capital Management's Revance Therapeutics, Inc. position peaked at $12K in Q4 2016.
  • 78 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2017.

Based on Elgethun Capital Management's 13F filing for Q1 2017, filed 11 May 2017.